CVS Health (CVS) opened 2026 with Q1 revenue of about US$100.4 billion and basic EPS of US$2.31, setting the tone for this reporting season. The company has seen quarterly revenue move from US$94.1 billion in Q1 2025 to US$100.4 billion in Q1 2026, while basic EPS over the same quarters shifted from US$1.41 to US$2.31, and trailing twelve month EPS now sits at roughly US$2.31 on revenue of US$405.7 billion. With reported net margins over the last year sitting at 0.7% and influenced by a large one off loss, this set of numbers puts profitability quality and earnings momentum firmly in focus for investors.

See our full analysis for CVS Health.

With the headline figures on the table, the next step is to see how these results line up with the prevailing market narratives around CVS Health's growth potential, risks, and earnings power.

Margins Sit at 0.7% After a $7.0b One Off Hit

• Over the last 12 months, CVS Health generated about US$405.7b in revenue and roughly US$2.9b in net income excluding extra items, which translates into a 0.7% net margin compared with 1.4% a year earlier and includes a US$7.0b one off loss.
• Bears highlight that compressed margins and that US$7.0b hit could signal pressure on long term profitability, and the numbers make that concern quite specific:
  • Trailing net income excluding extra items of about US$2.9b on US$405.7b of revenue leaves very little room for error if costs rise or reimbursement terms tighten further.
  • The one off loss is large relative to recent quarterly net income figures, which in this dataset range from a US$3.0b profit to a US$4.0b loss, so skeptics may question how repeatable any future margin recovery will be.

Bears who worry about those thin margins and the US$7.0b hit may want to see how that feeds into a fuller cautious case before deciding how much risk feels acceptable. 🐻 CVS Health Bear Case

P/E at 38x While DCF Fair Value Sits Far Higher

• The stock trades on a P/E of about 38x, well above the US healthcare industry at 22.4x and peers at 17.8x, yet the dataset also shows a DCF fair value of roughly US$251.47 against a current share price of about US$86.86.
• What is interesting for the bullish view is that high headline multiples sit next to a model that points to sizeable upside:
  • At US$86.86, the stock is below both the DCF fair value of about US$251.47 and the analyst price target of roughly US$97.81, which bulls argue reflects underappreciated cash flow potential.
  • The same dataset flags forecast earnings growth of about 21.2% a year, which bullish investors see as one reason the stock could grow into or even beyond today’s premium P/E over time.

If you are weighing a 38x P/E against a much higher DCF fair value, it is worth seeing how bullish investors connect these earnings trends to their long term case. 🐂 CVS Health Bull Case

Earnings Swing from US$3.1 Loss to US$2.3 EPS

• Over the last four reported quarters, basic EPS moved from a loss of about US$3.13 in Q3 2025 to US$2.32 in Q4 2025 and US$2.31 in Q1 2026, while trailing twelve month EPS sits at roughly US$2.31 on US$405.7b of revenue.
• Consensus narrative leans on long term earnings growth and integration benefits, and these EPS swings give you a sense of both the opportunity and the execution risk:
  • Analysts in this dataset expect earnings to reach about US$10.3b, or US$8.1 per share, by around April 2029, compared with roughly US$1.8b today, which assumes a very different profitability profile than the 0.7% trailing margin and recent loss affected period.
  • Those same expectations sit alongside a major risk flag that debt is not well covered by operating cash flow, so the path from a US$3.1 loss per share in Q3 2025 to higher long term earnings is unlikely to be smooth if cash generation does not keep pace.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CVS Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both risks and rewards in this story, it makes sense to check the numbers yourself and decide how comfortable you are with the trade off. To help frame that decision, start with these 2 key rewards and 4 important warning signs

See What Else Is Out There

Thin 0.7% margins after a US$7.0b one off loss, heavy earnings swings, and debt concerns all point to a business with limited room for error.

If those pressures leave you wanting steadier ground, use the solid balance sheet and fundamentals stocks screener (45 results) to quickly spot companies where stronger finances help support earnings through bumps like these.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.